Chronic kidney disease, heart failure and anemia

This publication has 42 references indexed in Scilit:

• Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome
  American Heart Journal, 2007
• Is early treatment of anaemia with epoetin- beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
  Nephrology Dialysis Transplantation, 2007
• Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia
  American Heart Journal, 2006
• Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
  New England Journal of Medicine, 2006
• Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study
  American Heart Journal, 2006
• Prevalence of anemia and effects on mortality in patients with heart failure
  American Heart Journal, 2005
• Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
  New England Journal of Medicine, 2004
• Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial
  European Heart Journal, 2004
• Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4)
  Journal of the American Society of Nephrology, 2004
• Human, rat, and mouse kidney cells express functional erythropoietin receptors
  Kidney International, 1999